Browsing Tag
Lumvoa
1 post
Viridian Therapeutics (VRDN) challenges Amgen’s Tepezza with broader thyroid eye disease approval
Viridian Therapeutics wins FDA approval for Lumvoa, its first commercial product, challenging Amgen in thyroid eye disease.